We found no significant difference in the risk of RBD (OR, 0.74; 95% CI, 0.29–1.86; I2 = 60.9%), EDS (OR, 0.21; 95% CI, 0.04–1.23; I2 = 0.0%), or RLS (OR, 1.01; 95% CI, 0.08–13.22; I2 = 74.6%) between PD patients carrying homozygous or compound heterozygous PRKN variants and iPD (Additional file 1: Figs. S5a, S6a, S7). Here, PRKN is linked to Parkinson disease.